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Abstract: Anti-HER2 antibody conjugated with quantum dots (anti-HER2ab-QDs) is a very 
recent fluorescent nanoprobe for HER2+ve breast cancer imaging. In this study we investigated 
in-vivo toxicity of anti-HER2ab conjugated CdSe/ZnS QDs in Wistar rats. For toxicity evalu-
ation of injected QDs sample, body weight, organ coefficient, complete blood count (CBC), 
biochemistry panel assay (AST, ALT, ALP, and GGTP), comet assay, reactive oxygen species, 
histology, and apoptosis were determined. Wistar rat (8–10 weeks old) were randomly divided 
into 4 treatment groups (n = 6). CBC and biochemistry panel assay showed nonsignificant 
changes in the anti-HER2ab-QDs treated group but these changes were significant (P , 0.05) in 
QDs treated group. No tissue damage, inflammation, lesions, and QDs deposition were found in 
histology and TEM images of the anti-HER2ab-QDs treated group. Apoptosis in liver and kidney 
was not found in the anti-HER2ab-QDs treated group. Animals treated with nonconjugated QDs 
showed comet formation and apoptosis. Cadmium deposition was confirmed in the QDs treated 
group compared with the anti-HER2ab-QDs treated group. The QDs concentration (500 nM) 
used for this study is suitable for in-vivo imaging. The combine data of this study support the 
biocompatibility of anti-HER2ab-QDs for breast cancer imaging, suggesting that the antibody 
coating assists in controlling any possible adverse effect of quantum dots.
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Introduction
Nanomaterials are emerging tools for diagnosis of various diseases and many other 
biomedical applications because of their unique properties rather than bulk materials.1–3 
Nanomaterial toxicity is a matter of concern and many in-vitro and in-vivo studies 
have suggested that the surface chemistry, release of metal ion, reactive oxygen species 
(ROS) production, cell apoptosis and break-down of nanomaterials are the possible 
causes of cellular toxicity.4–7 A new emerging class of nanomaterials known as QDs 
are brightly fluorescent, enabling their use as imaging probes in both in-vitro and in-
vivo systems, viz, molecular, cellular, and in-vivo imaging, tumor targeting, lymph 
node imaging, surface receptor targeting, and labeling.8–17 QDs can be coupled with 
biomolecules such as antibodies, peptides, carbohydrates, and small molecules to 
target early stage malignant tumors for imaging and diagnosis.18–21
The big challenge with the use of QDs is toxicity in living cells and animals due 
to their chemical composition of toxic heavy metal atoms (eg, cadmium, mercury, 
lead, arsenic).6,22–25 In-vitro toxicity is one of the most studied to date but few   in-vivo International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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studies have analyzed the physiological behavior of QDs.6,26,27 
  Previous studies have shown ambiguous results. Some 
in-vitro studies indicated cellular toxicity28,29 but others 
showed that cells loaded with QDs survived for weeks with-
out alteration in cell growth and division.30 The nature of 
QDs in an in-vivo system might be very different from that 
in an in-vitro system because the QDs can persist in organ 
tissues and directly interact with the living environment. 
Some in-vivo studies have shown the time-dependent 
increase in cadmium concentration in the liver and kidney 
after intravenous administration of cadmium-based QDs31 
but other in-vivo studies have shown no sign of toxicity 
in embryonic development at a concentration of 5 × 109 
QDs/cell.32 A study on Sprague-Dawley rats indicated no 
severe toxicity of CdSe/ZnS QDs for both short- (7 days) 
and long-term (80 days) exposure but some deposition of 
QDs in organ tissue was found.24
QDs cytotoxicity can be explained due to the release of 
Cd2+ ions and generation of ROS.4,5,33 Various strategies have 
been reported to minimize QDs toxicity, the most common 
of which are surface modifications and coatings with bio-
compatible molecules.28,29 Various types of primary and 
secondary coatings are used to enhance biocompatibility of 
QDs for medical applications. Capping these QDs with ZnS 
shells or coating with bovine serum albumin (BSA), poly-
ethylene glycol (PEG), glutathione, and silica rendered the 
QD cores less susceptible to oxidative degradation and less 
toxic.5,34,35 A study showed that the PEGylation of cationic 
QDs reduced toxicity at the same concentration compared 
to non-PEGylated QDs.25 QDs coating with additional bio-
compatible molecules (antibody, peptide, and small ligands) 
is also useful to control toxicity.
HER2 is a cell surface receptor found on the surface of 
certain cancer cells. HER2 is an orphan receptor because no 
known ligand is expressed for this receptor. It is encoded by a 
specific gene, the HER2/neu gene. The HER proteins regulate 
cell growth, survival, adhesion, migration and cell differenti-
ation. Overexpression of HER2 receptor is one cause of breast 
cancer, known as HER2-positive breast cancer. Anti-HER2 
antibody (ab) (herceptin) is the only recommended biological 
therapy for treatment of HER2-positive patients; after bind-
ing with HER2 receptor, anti-HER2ab checks cell division 
in breast tumors. QDs have been widely studied for cancer 
imaging and diagnosis, and anti-HER2ab-QDs has shown 
promising results for HER2 breast cancer detection.17,36,37 
This QDs conjugate offers great hope in early stage breast 
cancer imaging and diagnosis. The study reported investi-
gates the in-vivo toxicity of   anti-HER2-ab coated CdSe/ZnS 
QDs because this is useful for proper implementation of 
anti-HER2ab-QD conjugate for HER2 breast cancer imaging 
and diagnosis.
Materials and methods
chemicals
The following chemicals, all analytical grade, were used: 
quantum dot antibody binding kit (Qdot 525, Invitro-
gen, San Diego, CA), liver function assay kit (Transasia, 
India), YO-PRO-1 apoptosis assay kit (Invitrogen), 
anti-HER2 antibody (Invitrogen), propidium iodide (PI) 
(Sigma-Aldrich, St Louis, MO), heparins (Sigma-Aldrich), 
N, N-diethyl-pera-phenylenediam (DEPPD) (Sigma-
Aldrich), DCF-DA (Sigma-Aldrich), ethidium bromide 
  (Sigma-Aldrich), Triton X-100 (Sigma-Aldrich), LMP aga-
rose (Sigma-Aldrich), NM agarose (Sigma-Aldrich), anes-
thetic ether, ketamine/xylazine cocktail anesthesia, xylene, 
phosphate buffer saline, formalin, NaCl, NaOH, Na2HPO4, 
K2HPO4, HCl, H2O2, KOH, KCl, DMSO, EDTA, coomassie 
brilliant blue, phosphoric acid, ethanol, and lead citrate. All 
chemicals used were analytical grade.
Amino (Peg)-QDs conjugation  
with anti-her2 antibody
solution preparation for conjugation reaction
Conjugation of QDs with anti-HER2-ab was performed 
according to the manual provided with the QDs antibody 
conjugation kit (Qdot 525, Invitrogen, USA). Antibody solu-
tion (300 µL at a concentration of 1.0 mg/mL) was prepared 
in PBS and 40 µL of distilled water was added to the supplied 
dye labeled marker and mixed well. The solution mixture 
was stored at 2 to 6°C.
QDs nanocrystals activation and antibody reduction
To a centrifuge tube, 14 µL SMCC (Succinimidyl  -
4-(N-maleimidomethyl) cyclohexane-1-carboxylate) and 
125 µL QD nanocrystals were added and vortexed briefly 
to mix and incubated at 37°C for 1 hour. Anti-HER2 anti-
body (300 µL at 1.0 mg/mL) and di-thiothriol (6.1 µL) 
solution were added to a centrifuge tube and incubated 
for 30 minutes at room temperature. After incubation the 
mixture was desalted and QDs and antibody collected in a 
separate tube.
QDs conjugation with anti-her2 antibody
Reduced antibody and activated QD nanocrystals collected 
from the above reactions were mixed with each other and 
incubated for 1 hour at room temperature. The reaction was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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quenched by adding 10 µL (10 mM) 2-mercaptoethanol solu-
tions to the conjugation reaction and incubated for 30 minutes 
at room temperature.
separation of conjugates and nonconjugates
A gel filtration column was used for separation of 
anti-HER2ab-QDs from nonconjugated QDs. In brief, 
the conjugates collected as described above were added 
immediately to the two ultrafiltration devices (∼40 µL total 
volumes), allowed to enter the gel column, and then 50 µL 
PBS (pH 7.2) was gently added. The sample was allowed 
to elute by gravity. The first 10 drops were collected from 
the column because subsequent drops may have contained 
nonconjugated antibody molecules.
QDs characterization
QDs and anti-HER2ab-QDs were characterized by trans-
mission electron microscopy (TEM) and dynamic light 
scattering (DLS). After ultrasonication for 10 minutes, the 
sample was prepared by placing a drop of homogeneous 
suspension on a copper grid with a lacey carbon film 
and allowing it to dry in air. TEM images were observed 
with a JEOL-JEM-2100F TEM operating at 200 klV. 
The hydrodynamic diameters of QDs were evaluated by 
DLS. Samples were loaded into a sample holder and DLS 
data were collected by using a Malvern DLS apparatus 
(Nano-ZS, Malvern Instruments, Malvern, UK) with a 
633 nm He/Ne laser.
Animal treatment
The Wistar rat was selected as the model for the toxicity 
study of anti-HER2ab-QDs. All animals were kept in an 
animal house at 12 hours day/night cycle for 2 months. Food 
and water were supplied ad libitum. All animal were kept in 
stress-free, hygienic, and animal-friendly conditions. Wistar 
rats (8–10 weeks old) without tumors were selected randomly 
and divided into 4 treatment groups with 6 animals in each 
group. QDs and anti-HER2ab-QDs (100 µL of 500 nM solu-
tion) were injected intravenously twice in the tail vein, once 
on day 0 and once on day 15. One group (control group) 
was injected with PBS. Another group was selected of the 
size of the treated animal group in case of sudden death. All 
animals were anesthetized with an anesthesthetic cocktail of 
0.3 mL/250 g ketamine/xylazine (ketamine/xylazine cocktail: 
100 mg/mL ketamine + 20 mg/mL xylazine). The tail injection 
site was cleaned with xylene. The experiment was approved by 
the Animal Ethics Committee, Jawaharlal Nehru University, 
New Delhi, India and followed committee recommendations.
Blood sampling and complete blood 
count
Blood samples were collected routinely weekly from con-
trol and treated animals for complete blood count analysis. 
Blood (1.0 mL) was taken from the retro-orbital sinus by 
a heparin-coated capillary and collected with 20 mg/mL 
EDTA anticoagulant. Before taking the blood, animals were 
anesthetized with 0.3 mL/250 mg ketamine/xylazine. All 
animals were sacrificed at the same time and 5.0 mL blood 
was collected from a heart puncture. Of this sample, 1 mL 
was collected in 10% EDTA for complete blood count (CBC) 
and the remaining 4 mL of blood serum was collected for 
biochemistry panel assay and other biochemical assay.
The blood was analyzed for the number of erythrocytes, 
platelets, and total leukocytes, as well as neutrophils, lympho-
cytes, monocytes, eosinophils, and basophiles by an automated 
hematology counter (KX-21, Sysmex, Transasia, India).
Biochemistry panel analysis
We choose enzymatic parameters related to liver and kidney 
function. We determined the levels of various enzymes such 
as aspartate aminotransferase (AST), alanine aminotrasferase 
(ALT), gamma-glutamyl transpeptidase (GGTP), alkaline 
phosphatase (ALP), and total protein, albumin, globulin, 
bilirubin, and creatinine. Biochemistry assay for AST, ALT, 
ALP, and GGTP was performed according to the Interna-
tional Federation for Clinical Chemistry kinetics method 
and bilirubin by the diazo method. Total protein, albumin, 
and globulin were assayed by the method of Bradford.38 In 
brief, for each sample, 200 µL serum was mixed in 800 µL of 
Bradford reagent. Optical density (at 595 nm) was measured 
after 10 minutes incubation in the dark. BSA was used as 
a standard protein. AST, ALT, ALP, and GGTP assay was 
performed with an enzyme assay kit using end-point method 
and data obtained by spectrophotometry (Erba CHEM-5 
Plus v2).
reactive oxygen species assay  
from serum
The ROS assay was performed by N, N-diethyl-pera-
  phenylenediamine (DEPPD) staining.39 In brief, 5 µL serum 
was added to 140 µL of 0.1 M sodium acetate buffer (pH 4.8) 
at 37°C in a 96-well plate (microtiter plate). Samples were 
taken in triplicate and 100 µL of the mixed DEPPD solution 
(DEPPD was dissolved in 0.1 M sodium acetate buffer [pH 
4.8]) and ferrous sulfate (4.37 µm ferrous sulfate dissolved 
in 0.1 M sodium acetate buffer, pH 4.8) at a ratio of 1:25 
was added to each well to initiate reaction. Thereafter, the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  microtiter plate was then incubated at 37°C for 5 minutes. 
Absorbance was measured by a spectrophotometer plate 
reader (Spectra Max M2) at 505 nm. ROS levels from serum 
were calculated from a calibration curve of H2O2 and expressed 
as hydrogen peroxide equivalent (1 unit = 1.0 mg H2O2/L). 
The calibration curve for standard solution was obtained by 
calculating slopes from an optical density graph.
comet assay from blood
A comet assay (also referred to as single-cell gel electro-
phoresis) was used to determine DNA damage. Cell lysate 
was prepared from blood after centrifugation at 1500 rpm 
for 5 minuntes. For primary coating, one-sided frosted glass 
plates were coated with 0.7% low melting point agarose. 
Cell lysate was prepared with prechilled lysis solution (2.5 
M NaCl, 0.1 M EDTA, 10 mM Tris base, pH 10) with 1% 
Triton X 100 (Sigma-Aldrich) for 1 hour at 4°C and 10 µL 
cell lysate was embedded in 0.7% low melting point agarose 
on one-sided frosted comet slides. Cells were then subjected 
to denaturation in alkaline buffer (0.3 M NaCl, 1 mM EDTA) 
for 1 hour in the dark at room temperature. After lysing over-
night, the slides were removed and placed in a horizontal slab 
of an electrophoresis assembly. One liter of electrophoresis 
buffer was gently poured into the assembly. All plates were 
electrophorsed at 0.7 V/cm and 250 mA for 30 minutes. The 
slides were neutralized in neutralization buffer (0.5 M Tris-
HCl, pH 7.5) for 20 minutes followed by dehydration in 70% 
ethanol. All slides were air dried at room temperature and 
stained with 5 µg/mL PI dye. The tail length, tail moments, 
and tail migration were measured by using Comet Assay IV 
software (Perspective Instruments, Haverhill, Suffolk, UK) 
as a function of DNA damage. For measurement, 25 comets 
were scored and analyzed for each sample.
Body weight and coefficients of organs
Body weight of all animals was recorded after sacrifice by 
an excess dose of anesthetic ether and cervical dislocation. 
Organs such as liver, kidney, spleen, and brain were removed 
and weight was measured immediately after removal. After 
weighing the body and organs, the coefficients of liver, kidney, 
spleen, and brain weight to body weight were calculated as 
the ratio of tissue wet weight (g) to body weight (g).
Microscopic analysis of organ tissue
Liver, kidney, and spleen were removed and fixed with 
10% formalin. Organ samples were embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin. Liver, 
kidney, and spleen slides were examined by light   microscopy 
through a 40× objective lens by a blinded veterinary 
pathologist.
For TEM analysis of liver and kidney, small pieces of 
tissue (∼2 mm) were fixed in 2.5% gluteraldehyde for 2 to 
4 hours and washed in 0.2 M phosphate-buffered saline 
(PBS). Post fixation was done with 1% osmium tetra-oxide 
for 1 hour. Cells were washed in PBS and dehydrated in 
alcohol (50%, 70%, 80%, 95%, and 100%). Cells were fur-
ther treated with propylene oxide (30 minutes), propylene 
oxide-resin mixture (overnight), and pure resin (48 hours). 
Embedding was done in BEEM (better equipment for elec-
tron microscopy) capsules using pure Spurr’s low viscosity 
resin at 80°C for 48 hours. Ultrathin sections (70 nm) were 
taken using Leica EM UC 6 ultramicrotom and stained with 
1% lead acetate. Sections were examined under JEOL-JEM-
2100F TEM operating at 200 kV.
Quantitative assay of cadmium
Liver and kidney of all animals were removed and burned 
at 200°C for 20 minutes, 1.0 g organ powder was used for 
EDXRF analysis. Pressed powdered samples were prepared 
by using 10 tons pressure to the sample, boric acid used with 
organ powder as a supporter base. Cadmium concentration 
was analyzed in pressed powdered sample with energy dis-
persive X-ray fluorescence (EDXRF) spectroscopy (Epsilon5 
PANalytical).
cell apoptosis
Single cell suspension was prepared, washed in cold PBS 
and the cell density was adjusted to ∼1 × 106 cells/mL in 
PBS. Assay was done according to the manual provided with 
apoptosis assay kit (Molecular Probe, Invitrogen). In brief, 
1 mL assay volume was added to 1 µL YO-PRO stock solu-
tion and 1 µL PI stock solution to each 1 mL of cell suspen-
sion. Samples were incubated on ice for 20 to 30 minutes. 
Samples were analyzed for stained cells by flow cytometry, 
using 488 nm excitation with green fluorescence emission for 
YO-PRO-1 (ie, 530/30 band pass) and red fluorescence emis-
sion for PI (ie, 610/20 band pass), gating on cells to exclude 
debris. The cell population was separated into 3 groups: live 
cells showed a low level of green fluorescence, apoptotic cells 
showed an incrementally higher level of green fluorescence, 
and dead cells showed both red and green fluorescence.
statistical analysis
Statistical analysis was performed with a 2-sample t-test, 
unknown and unequal variances, comparing each sample 
group to the related control group at a significance level of International Journal of Nanomedicine 2011:6
Figure 1 TeM image of quantum dots (QDs) and anti-her2ab-QDs. Bar size is 
20 nm in both images and analysis was done at 200 kv.
11.7 ± 2.2 nm
a) Non-conjugated QDs
Hydrodynamic diameter/nm
N
u
m
b
e
r
 
(
%
)
30
20
10
0
11 0 100 1000
15.7 ± 3.7 nm
b) Anti- HER2Ab conjugated QDs
Hydrodynamic diameter/nm
N
u
m
b
e
r
 
(
%
)
25
20
10
15
5
0
11 0 100 1000
Figure 2 Dynamic light scattering histogram for hydrodynamic diameter detection 
of  quantum  dots  (QDs)  and  anti-her2ab-QDs  in  10  mM  PBs  buffer:  a)  QDs 
(525 nm) and b) anti-her2ab-QDs (525 nm). The hydrodynamic sizes of the QDs 
and anti-her2ab-QDs were 11.7 nm and 15.7 nm, respectively.
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Figure 3 Body weight of Wistar rats following injection of quantum dots (QDs) 
and anti-her2ab-QDs. Mean and standard deviation of body weight of Wistar rats 
treated with QDs, anti-her2ab-QD, and phosphate buffered saline control were 
not significantly different over a 2-month period.
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0.05 (95%). The results are presented as mean ± standard 
deviation (SD).
Results
QDs characterization
QDs were characterized by TEM (Figure 1) and DLS 
(Figure 2). In the TEM image, clusters of nanoparticles 
showed the inorganic core of QDs. Images taken by TEM 
showed a 5 to 7 nm size range of nonconjugated QDs and 
anti-HER2ab-QDs. Only the core of the QDs could be imaged 
by TEM; DLS analysis was done for hydrodynamic size 
measurement. Hydrodynamic diameter of anti-HER2ab-QDs 
in PBS characterized by DLS was 15.7 ± 3.7 nm, while the 
diameter of nonconjugated PEG-QDs was 11.7 ± 2.2 nm. 
Results from DLS clearly indicated the antibody molecule 
binding with QDs.
Body weight and organ coefficients
Throughout the study no animals showed any unusual 
response. No behavioral changes were found in any group. 
Body weight increased nonsignificantly with age during 
the experiment (Figure 3) and no weight loss was found in 
any experimental group. No significant changes were found 
in organ coefficients of liver, kidney, spleen, and brain in 
any treatment group except QDs treated liver and kidney 
(Figure 4). Upon injection, and throughout the entire study, 
no unusual behavior or differences between groups were 
observed, including labored breathing, difficulties in moving, 
hunching, or unusual interactions with cage mates.
hematology results
No significant changes in CBC were found in any treatment 
group except hemoglobin concentration and white blood 
cell count (WBC) count in the QDs treated group. After 3 
weeks, hemoglobin concentration had significantly decreased 
in the QDs treated group but no decrease was measured at 
the end of the experiment, and no significant changes were 
observed in any other treatment group (Figure 5A). WBC 
count, especially lymphocytes and neutrophils, significantly International Journal of Nanomedicine 2011:6
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Figure 4 Coefficient of organs (liver, kidney, spleen, and brain) for Wistar rats 
treated with quantum dots (QDs), anti-HER2ab-QDs and PBS. Coefficient of organs 
is the ratio of weight of the organs (g) to animal weight (g). No significant difference 
found at α = 0.05. statistical analysis was performed with a 2-sample t-test, unknown 
and unequal variances, comparing each sample group to the related control group. 
Note: *denotes statistically significant results at α = 0.05.
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Figure 5 hematology analysis for the Wistar rats treated with quantum dots (QDs), anti-her2-ab-QDs, and phosphate buffered saline. A–F) These results show mean 
and standard deviation of hemoglobin (A), white blood cells (B), neutrophils (c), lymphocytes (D), red blood cell count (e), and platelets (F). error bars represent standard 
deviation. statistical analysis was performed with a 2-sample t-test, unknown and unequal variances, comparing each sample group to the related control group. 
Note: *denote statistically significant results at α = 0.05.
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increased (P , 0.05) in the QDs treated group (Figure 5C, D). 
RBC count nonsignificantly changed in all treated groups 
(Figure 5E). There were no significant changes in platelets 
count throughout the experiment in any group as compared 
to control (Figure 5F).
Biochemistry panel assay for organs 
function
Changes in the level of total protein, albumin, and globulin 
were not significant in any experimental group while the levels 
of ALT, AST, and ALP increased significantly (P , 0.05) 
in QDs treated group. The changes were   nonsignificant in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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degradation products cause tissue damage, inflammation, or 
lesions resulting from toxic exposure. Overall, no apparent 
histopathological abnormalities or lesions were observed 
in liver, kidney, and spleen of anti-HER2ab-QDs treated 
animal. QDs treated animals exhibited moderate bile-duct 
hyperplasia in liver with concurrent moderate centrilobular 
fibrosis, mild pigment accumulation, and moderate multi-
focal necrosis. Representative histology results are shown 
in Figure 10. In kidney tubular dilatation, cast formation, 
mineralization, and inflammation were noted in QDs 
treated group and moderate inflammation also noted in 
anti-HER2ab-QDs animals.
In order to investigate the toxicity of QDs and the deposi-
tion within the cells or on the cellular membrane, TEM was 
performed in all treated group by using single staining. Liver 
and kidney of treated and untreated animals showed no abnor-
mality and cellular damage in any treated group (Figure 11). 
Liver cells showed no damage. Rough endoplasmic reticulum, 
mitochondrial compartment, and nuclear membrane did not 
show any deformity. QDs and anti-HER2ab-QDs seemingly 
do not damage the liver and kidney. Single staining was used 
to relocate QDs nanocrystals in the TEM image.
Figure 6 (To be continued).
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the anti-HER2ab-QDs treated group (Figure 6A, B, C). The 
increase in GGTP level was directly associated with kidney 
function while the increase in the level of bilirubin was 
directly associated with liver function. Changes in GGTP 
level were nonsignificant and bilirubin level increased 
  significantly in both the QDs and anti-HER2ab-QDs treated 
groups (Figure 6D, E).
rOs estimation
An increase in ROS level was detected in both QDs and anti-
HER2ab-QDs treated groups. ROS increase was higher in 
both anti-HER2ab-QDs and QDs treated groups than in the 
control. In QDs treated animals a significantly higher increase 
was observed compared with control and anti-HER2ab-QDs 
treated animals. ROS was 6 U in the anti-HER2ab-QD group 
and 14 U in QDs treated animals. These results indicate that 
the HER2ab coated QDs are less toxic than noncoated QDs 
(Figure 7).
cadmium concentration in liver  
and kidney
Cadmium concentration in liver, kidney, and spleen was 
calculated by energy dispersive X-ray fluorescence (EDXRF) 
spectroscopy and expressed in µg/gm tissue (Figure 8). 
In QDs treated animals the concentrations of cadmium in 
liver and kidney were 3.85 ± 0.06 µg and 1.12 ± 0.1 µg, 
respectively, higher than in anti-HER2ab-QDs (2.9 ± 0.12 µg, 
0.49 ± 0.05 µg) and control (0.05 ± 0.01 µg, 0.034 ± 0.01 µg) 
animals, respectively. In spleen concentrations in QDs, 
anti-HER2ab-QDs, and control samples were 0.11 ± 0.02, 
0.073 ± 0.01 and 0.021 ± 0.01 µg, respectively.
comet assay for DNA damage
Figure 9 shows the comet assay genotoxicity study results 
for QDs and anti-HER2ab-QDs treated animals. Slides were 
assayed for single strand DNA breaks. It is evident from the 
graph that the comet length was higher in QDs treated samples 
than anti-HER2ab-QDs and its corresponding control. Tail 
lengths were 53.4 ± 2.5 µm, 10.3 ± 1.2 µm, and 1.3 ± 0.2 µm 
in QDs, anti-HER2ab-QD, and control groups, respectively. 
Tail migration was 39.5 ± 2.1 µm, 11.0 ± 0.6 µm, and 
0.4 ± 0.03 µm and tail moment was 16.4 ± 1.3, 6.5 ± 0.4, 
and 0.3 ± 0.01 in QDs, anti-HER2ab-QD, and control groups, 
respectively.
Microscopic examination
Histological assessment of tissues was conducted to 
determine whether or not the QDs themselves or their International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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cell apoptotic study
Apoptotic cells are permeable to YO-PRO-1 green fluorochrome 
and impermeable to PI. Thus, use of combined   YO-PRO-1 and 
PI dyes provides a sensitive indicator for apoptosis. Typical 
histograms of liver and kidney cells labeled with YO-PRO-1/PI 
are shown in Figure 12A–F. Using   YO-PRO-1/PI, 3 peaks of 
cells were clearly detected: i) necrotic cells, labeled with PI, 
M1 peak, ii) living cells, with low permeability membranes, 
M2 peak, and iii) apoptotic cells (ie, living cells with modified 
membranes, M3 peak. Induction of apoptosis in the liver and 
kidney cells increased the number of living cells exhibiting a 
high permeability to YO-PRO-1 (Figure 12C, F). Treatment 
with QDs increased the proportion of cells exhibiting high 
permeability to YO-PRO-1 (Figure 12C, F) compared to 
control and anti-HER2ab-QDs treated groups (Figure 12A, 
B, D, E). Data indicated that the nonconjugated QDs induced 
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factors determing toxicity.40 A research group in Toronto 
University showed that the QDs are nontoxic in low 
  concentrations, which can be used for bioimaging.24 It has 
also been reported by another group that QDs at low or 
high doses do not affect phenotypic response in cells.41 
In our findings, no unusual physiological responses were 
shown in any treated group. Body weight increased accord-
ing to age in all groups and no significant decrease was 
observed in any treated group (Figure 3). Nonsignificant 
changes in organ coefficients in all groups indicated no 
severe damage, tumor progression, or inflammation in 
any major organ, such as liver, kidney, spleen, and brain 
(Figure 4). QDs samples were intravenously injected 
in all animal groups, interacting in the whole body first 
with blood and its components. Interaction of QDs with 
blood components and the release of Cd2+ ions may cause 
various immunogenic responses, inflammation, and 
changes in hematological factors such as WBCs, platelets, 
hemoglobin, and the blood components involved in RBC 
maturation.42 Changes in hematological parameters were 
nonsignificant in all treated groups except WBC count 
(Figure 5) (P , 0.05). Where WBCs counts differed, the 
percentage of   lymphocytes responded differently from that 
of neutrophils. WBCs returned to the control value within 
6 weeks, while neutrophils levels changed significantly 
during the whole experiment compared with control. These 
changes can be associated with immunogenic response of 
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tail length). statistical analysis was performed with a 2-sample t-test, unknown and 
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apoptosis to some extent but anti-HER2ab-QDs and control 
group animals showed no apoptosis.
Discussion
Because of the increasing use of QDs in biomedical 
research, it has become extremely important to understand 
the impact and toxicity of QDs on cells and ultimately on 
the living system. Very few in-vivo toxicity studies of 
QDs have been published and some of these have sug-
gested that surface coating of QDs is one of the dominant 
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QDs because the size of the QDs used in this study is very 
close to the size of immunogens.43,44 The changes in WBCs 
count were nonsignificant in Wistar rats treated with anti-
HER2-ab coated CdSe QDs,24 because the nanocrystals are 
less toxic when their surface is better protected by coating 
with various biocompatible materials.
The clearance rate of nanoparticles from the body 
depends on their size and the coated materials used. QDs 
A
B
C
Figure 11 TeM images of liver and kidney of quantum dots (QDs) and anti-her2ab-QDs treated Wistar rats: A) control (liver), B) animals treated with QDs (liver), C) animals 
treated with anti-her2ab-QDs, D) control kidney, E) animals treated with QDs, F) animals treated with anti-her2ab-QDs. single staining was used for all TeM analysis. random 
circle in the image show nucleolus, arrow in white color show mitochondria and red arrow indicate rer (rough endoplasmic reticulum).
D
E
F
  biocompatibility is directly associated with its rate of   clearance 
from the body.45 Long-term deposition of the QDs may be 
hazardous to the body. EDXRF results indicates an increased 
level of cadmium in liver and kidney of QDs treated animals, 
but cadmium level was not significantly high in the spleen.26 
From the EDXRF results QDs deposition was evident in liver 
and kidney of QDs treated animals (Figure 8). It is evident 
from previous studies that the long-term deposition may International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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cause changes in the blood serum enzymatic composition, 
  inflammation, tissue damage, and genotoxic effect.29,46,47 
Serum proteins and the level of particular enzymes in blood 
serum are good indicators of hepatocellular injury, hepatic 
inflammation, kidney function impairment, and cholestesis 
  (reduction in flow of bile juice).48 ALP concentration decreased 
significantly (P , 0.05) in the QDs treated group but the 
changes were nonsignificant in the anti-HER2ab-QDs group 
(Figure 6). An increase in ALP is directly associated with liver 
function. A very high ALP level indicates abnormality in liver 
and kidney function. Elevated serum ALP activity is related to 
be symptomatic of that found in liver diseases, biliary system, 
and to those of pancreas. GGTP level did not significantly 
change in any group. On the other hand, ALT and AST levels 
significantly increased in the QDs treated group but not in the 
anti-HER2ab-QDs group. Changes in ALT and AST levels are 
indicators of hepatocellular level damage. An increased level 
of these enzymes in QDs treated group confirms impairment 
of hepatic function. Biochemical results indicated that the 
anti-HER2ab-QDs were not toxic to animal systems in the 
concentrations used for this experiment, while QDs treated 
animals showed significant changes (Figure 6).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Generation of ROS by CdSe QDs has been reported 
by many groups.29,49 Increased ROS can produce high 
amounts of H2O2 in the cellular environment, resulting in 
modification to and damage of cellular components, such 
as lipids, proteins, and DNA.50,51 ROS are known to medi-
ate cell death in a variety of cell types. A previous study 
reported production of ROS by nonconjugated CdSe/ZnS 
QDs in the presence and absence of light.49 In our find-
ings ROS level was higher in the QDs treated group than 
in anti-HER2ab-QDs and control groups (Figure 7). An 
increase in ROS level is the indicator of toxicity induced 
by QDs, which was lower in anti-HER2ab-QDs treated 
animal group.29 On the other hand, the higher comet tail 
migration noted in the QDs group indicates genotoxicity 
(Figure 9). In the genotoxicity study, tail migration was 
slightly higher in the anti-HER2ab-QDs group than in 
control, because the QDs core was highly protected in 
the anti-HER2ab-QDs treated animals and the rate of 
clearance was high. The potential breakdown of QDs with 
time and the persistence of Cd2+ and Se2– ions over a week 
or two in the liver and kidney is directly associated with 
toxicity. Previous studies have shown that bare QDs can 
injure cells, inducing damage to the plasma membrane, 
mitochondrion, and nucleus.29
Histological examination of liver, kidney and spleen did 
not show severe toxicity but inflammation was observed in 
the liver of QDs treated animals. Spleen and kidney also 
indicated some moderate pathological symptom but no 
evident symptoms were found in anti-HER2ab-QDs treated 
animals (Figure 10).24 QDs deposition was not evident in 
TEM analysis of the liver and kidney. No evidence of tissue 
damage appeared in TEM image analysis and the cellular 
structure was intact (Figure 11). A loss of plasma membrane 
integrity is considered an early event in necrosis and a late 
event in apoptosis.24,46,47 Nuclear condensation with DNA 
fragmentation is a mark of apoptotic cell death, whereas, in 
necrosis, nuclei are swollen. Cell apoptosis was not evident 
in liver and kidney of the anti-HER2ab-QDs treated group 
(Figure 12). Overall, the findings indicate that anti-HER2ab-
QDs are not toxic in the concentrations used above. Usually 
the concentrations used for in-vitro and in-vivo bioimaging 
are less than the concentrations we tested for toxicity assess-
ment. This study supports the use of anti-HER2ab-QDs for 
breast cancer bioimaging. Anti-HER2ab-QDs can be used 
as probe for breast tumor detection at the initial stage tumor. 
These QDs can also be conjugated with other antibody and 
small ligand for imaging, diagnosis and drug targeting of 
other cancer types.
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